Intralesional rituximab treatment for atypical refractory granuloma faciale
Ann Dermatol Venereol
.
2021 Dec;148(4):272-274.
doi: 10.1016/j.annder.2021.06.001.
Epub 2021 Aug 26.
Authors
E Joly
1
,
A Duval-Modeste
2
,
R Sabatier
3
,
G Arhant
4
,
L Cellier
4
,
M Mouthon
5
,
F Comoz
5
,
P Joly
2
,
A Dompmartin
6
Affiliations
1
Dermatology Department, CHU Caen, 14033 Caen, France; Université de Caen Basse-Normandie, Faculté de médecine, 14000 Caen, France. Electronic address: elisa.joly@chu-reunion.fr.
2
Dermatology Department, CHU Rouen, 76000 Rouen, France.
3
Cardiology Department, CHU Caen, 14033 Caen, France.
4
Pathology Department, CHU Rouen, 76000 Rouen, France.
5
Pathology Department, CHU Caen, 14033 Caen, France.
6
Dermatology Department, CHU Caen, 14033 Caen, France; Université de Caen Basse-Normandie, Faculté de médecine, 14000 Caen, France.
PMID:
34456047
DOI:
10.1016/j.annder.2021.06.001
No abstract available
Keywords:
Facial granuloma of Lever; Granuloma faciale; IgG4-related disease; Rituximab.
Publication types
Letter
MeSH terms
Connective Tissue Diseases*
Facial Dermatoses* / drug therapy
Granuloma / drug therapy
Humans
Rituximab
Skin Neoplasms*
Substances
Rituximab